1
|
Nelson RW, Chen Y, Venezia OL, Majerus RM, Shin DS, Carrington MN, Yu XG, Wesemann DR, Moon JJ, Luster AD. SARS-CoV-2 epitope-specific CD4 + memory T cell responses across COVID-19 disease severity and antibody durability. Sci Immunol 2022; 7:eabl9464. [PMID: 35857584 PMCID: PMC9097883 DOI: 10.1126/sciimmunol.abl9464] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 04/15/2022] [Indexed: 01/14/2023]
Abstract
CD4+ T cells are central to long-term immunity against viruses through the functions of T helper 1 (TH1) and T follicular helper (TFH) cell subsets. To better understand the role of these subsets in coronavirus disease 2019 (COVID-19) immunity, we conducted a longitudinal study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific CD4+ T cell and antibody responses in convalescent individuals who seroconverted during the first wave of the pandemic in Boston, MA, USA, across a range of COVID-19 disease severities. Analyses of spike (S) and nucleocapsid (N) epitope-specific CD4+ T cells using peptide and major histocompatibility complex class II (pMHCII) tetramers demonstrated expanded populations of T cells recognizing the different SARS-CoV-2 epitopes in most individuals compared with prepandemic controls. Individuals who experienced a milder disease course not requiring hospitalization had a greater percentage of circulating TFH (cTFH) and TH1 cells among SARS-CoV-2-specific cells. Analysis of SARS-CoV-2-specific CD4+ T cells responses in a subset of individuals with sustained anti-S antibody responses after viral clearance also revealed an increased proportion of memory cTFH cells. Our findings indicate that efficient early disease control also predicts favorable long-term adaptive immunity.
Collapse
Affiliation(s)
- Ryan W. Nelson
- Division of Immunology, Boston Children’s Hospital, Harvard Medical School; Boston, MA, USA
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
| | - Yuezhou Chen
- Department of Medicine, Division of Allergy and Clinical Immunology, Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
| | - Olivia L. Venezia
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
- Infectious Disease Division, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
| | | | - Daniel S. Shin
- Division of Immunology, Boston Children’s Hospital, Harvard Medical School; Boston, MA, USA
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
| | - MGH COVID-19 Collection & Processing Team†
- Division of Immunology, Boston Children’s Hospital, Harvard Medical School; Boston, MA, USA
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
- Department of Medicine, Division of Allergy and Clinical Immunology, Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
- Queens University of Charlotte, Charlotte, NC, USA
- Ragon Institute of MGH, MIT and Harvard; Cambridge, MA, USA
- Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute; Bethesda, MD, USA
- Infectious Disease Division, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
- Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
| | - Mary N. Carrington
- Ragon Institute of MGH, MIT and Harvard; Cambridge, MA, USA
- Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute; Bethesda, MD, USA
| | - Xu G. Yu
- Ragon Institute of MGH, MIT and Harvard; Cambridge, MA, USA
- Infectious Disease Division, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
| | - Duane R. Wesemann
- Department of Medicine, Division of Allergy and Clinical Immunology, Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
- Ragon Institute of MGH, MIT and Harvard; Cambridge, MA, USA
| | - James J. Moon
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
- Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
| | - Andrew D. Luster
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA
| |
Collapse
|
2
|
Sant KE, Venezia OL, Sinno PP, Timme-Laragy AR. Perfluorobutanesulfonic Acid Disrupts Pancreatic Organogenesis and Regulation of Lipid Metabolism in the Zebrafish, Danio rerio. Toxicol Sci 2019; 167:258-268. [PMID: 30239974 DOI: 10.1093/toxsci/kfy237] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Following the phase-out of highly persistent perfluorosulfonates in the United States from non-stick and stain-resistant products in the early 2000s, perfluorobutanesulfonic acid (PFBS) has replaced these compounds as a primary surfactant. Measurements of PFBS in environmental and human samples have been rising in recent years, raising concerns about potential negative health effects. We previously found that embryonic exposures to a related compound, perfluorooctanesulfonic acid (PFOS), decreased pancreas length and insulin-producing islet area in zebrafish embryos (Danio rerio). The objective of this study was to compare the effects of PFBS exposures on pancreatic organogenesis with our previous PFOS findings. Dechorionated zebrafish embryos from two different transgenic fish lines (Tg[insulin:GFP], Tg[ptf1a:GFP]) were exposed to 0 (0.01% DMSO), 16, or 32 µM PFBS daily beginning at 1 day post fertilization (dpf) until 4 and 7 dpf when they were examined using fluorescent microscopy for islet area and morphology, and exocrine pancreas length. PFBS-exposed embryos had significantly increased caudal fin deformities, delayed swim bladder inflation, and impaired yolk utilization. Incidence of fish with significantly stunted growth and truncated exocrine pancreas length was significantly increased, although these two effects occurred independently. Islet morphology revealed an increased incidence of severely hypomorphic islets (areas lower than the 1st percentile of controls) and an elevated occurrence of fragmented islets. RNA-Seq data (4 dpf) also identify disruptions in regulation of lipid homeostasis. Overall, this work demonstrates that PFBS exposure can perturb embryonic development, energy homeostasis, and pancreatic organogenesis.
Collapse
Affiliation(s)
- Karilyn E Sant
- Department of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts 01003.,Division of Environmental Health, School of Public Health, San Diego State University, San Diego, California 92182
| | - Olivia L Venezia
- Department of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts 01003
| | - Paul P Sinno
- Department of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts 01003
| | - Alicia R Timme-Laragy
- Department of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts 01003
| |
Collapse
|
3
|
Roy MA, Sant KE, Venezia OL, Shipman AB, McCormick SD, Saktrakulkla P, Hornbuckle KC, Timme-Laragy AR. The emerging contaminant 3,3'-dichlorobiphenyl (PCB-11) impedes Ahr activation and Cyp1a activity to modify embryotoxicity of Ahr ligands in the zebrafish embryo model (Danio rerio). Environ Pollut 2019; 254:113027. [PMID: 31421573 PMCID: PMC7027435 DOI: 10.1016/j.envpol.2019.113027] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 07/29/2019] [Accepted: 08/04/2019] [Indexed: 05/25/2023]
Abstract
3,3'-dichlorobiphenyl (PCB-11) is an emerging PCB congener widely detected in environmental samples and human serum, but its toxicity potential is poorly understood. We assessed the effects of three concentrations of PCB-11 on embryotoxicity and Aryl hydrocarbon receptor (Ahr) pathway interactions in zebrafish embryos (Danio rerio). Wildtype AB or transgenic Tg(gut:GFP) strain zebrafish embryos were exposed to static concentrations of PCB-11 (0, 0.2, 2, or 20 μM) from 24 to 96 h post fertilization (hpf), and gross morphology, Cytochrome P4501a (Cyp1a) activity, and liver development were assessed via microscopy. Ahr interactions were probed via co-exposures with PCB-126 or beta-naphthoflavone (BNF). Embryos exposed to 20 μM PCB-11 were also collected for PCB-11 body burden, qRT-PCR, RNAseq, and histology. Zebrafish exposed to 20 μM PCB-11 absorbed 0.18% PCB-11 per embryo at 28 hpf and 0.61% by 96 hpf, and their media retained 1.36% PCB-11 at 28 hpf and 0.84% at 96 hpf. This concentration did not affect gross morphology, but altered the transcription of xenobiotic metabolism and liver development genes, impeded liver development, and increased hepatocyte vacuole formation. In co-exposures, 20 μM PCB-11 prevented deformities caused by PCB-126 but exacerbated deformities in co-exposures with BNF. This study suggests that PCB-11 can affect liver development, act as a partial agonist/antagonist of the Ahr pathway, and act as an antagonist of Cyp1a activity to modify the toxicity of compounds that interact with the Ahr pathway.
Collapse
Affiliation(s)
- Monika A Roy
- Department of Environmental Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA; Biotechnology Training Program, University of Massachusetts Amherst, Amherst, MA 01003, USA
| | - Karilyn E Sant
- Department of Environmental Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA
| | - Olivia L Venezia
- Department of Environmental Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA
| | - Alix B Shipman
- Department of Environmental Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA
| | - Stephen D McCormick
- US Geological Survey, Leetown Science Center, S.O. Conte Anadromous Fish Research Laboratory, Turners Falls, MA 01376, USA
| | - Panithi Saktrakulkla
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA 52242, USA
| | - Keri C Hornbuckle
- Department of Civil and Environmental Engineering and IIHR-Hydroscience and Engineering, University of Iowa, Iowa City, IA 52242, USA
| | - Alicia R Timme-Laragy
- Department of Environmental Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA.
| |
Collapse
|